Syringe Services Programs are Essential Public Health Infrastructure: Providing Services During the COVID-19 Pandemic

July 29th, 2020
Session Hosts

Alice K. Asher, Rn, PhD
Senior Service Fellow, Centers for Disease Control and Prevention

Daniel Raymond,
Deputy Director of Planning and Policy, Harm Reduction Coalition

Laura Pegram, MSW, MPH
Associate Director, Drug User Health, NASTAD
COVID-19 and Syringe Services programs: Impact and Interim Guidance

Alice K. Asher, RN, PhD
Senior Service Fellow, Centers for Disease Control and Prevention

Syringe Services Programs are Essential Public Health Infrastructure: Providing Services During the COVID-19 Epidemic

July 29, 2020
Roadmap for today’s discussion

Background:
- The public health impact of syringe services programs (SSPs)
- Impact of COVID-19 on SSPs

Brief overview of CDC’s interim guidance for SSPs during the COVID-19 pandemic:
- COVID-19 related guidance
- Providing harm reduction services
Syringe services programs prevent transmission of blood-borne infections

- Access to sterile injection equipment can help prevent blood-borne infections, skin infections and endocarditis
- Healthcare provided at SSPs can catch problems early and provide easy-to-access treatment
- In Philadelphia, SSPs averted 10,582 HIV infections over 10 years; 1-year return on investment of $243.4M

*Medications for opioid use disorder

Source: https://www.cdc.gov/ssp/syringe-services-programs-summary.html; Ruiz, et al, JAIDS, 2019
Nearly 30 years of research demonstrates that SSPs are safe, effective and provide critical services

- SSPs engage people who inject drugs in healthcare and other social service
  - Improved access to primary care
  - 5 times as likely to enter treatment for a substance use disorder
  - 3 times as likely to stop injecting than those who don’t use the programs
  - Improved treatment retention
- SSPs do not increase crime
- SSPs help keep communities clean by providing safe needle disposal
SSPs have been significantly impacted by COVID-19

Based on data collected from 173 syringe exchanges that responded to a survey conducted by the North American Syringe Exchange Network (NASEN) - March 31-April 16, 2020

Glick et al, *AIDS and Behavior*, 2020
SSPs are adapting services as a result of COVID-19

- Change in distribution models
- Measures to ensure staff and client safety
- Sterile injecting supplies and naloxone prioritized over screening for infectious disease
- SARS-CoV-2 testing

Glick et al, *AIDS and Behavior*, 2020
CDC interim guidance on SSPs during COVID-19 pandemic

- SSPs should be considered essential
- Continuity of harm reduction services can reduce overdoses and transmission of infectious disease
- SSPs can help detect COVID-19 cases and prevent additional cases
Preventing transmission of SARS-CoV-2 at SSPs

- Ensure all clients, staff, and volunteers wear masks at all times to protect others

- Staff and volunteers should wash hands regularly
  - Clients should clean hands upon entry

- Ensure all clients, staff, and volunteers maintain physical distancing as much as possible
  - Consider services outdoors
  - Mail-order, delivery alternatives

- Promote flexible and non-punitive sick leave policies for SSP staff
Protecting SSP clients

- Screen all clients for possible COVID-19 symptoms
- Conduct SARS-CoV-2 testing at the SSP if feasible
  - Partnerships with local health department or healthcare organizations may facilitate access to testing and care
- Any clients with suspected or confirmed SARS-CoV-2 should be excluded from the facility until they meet CDC’s criteria for discontinuation of home isolation
- Provide hygiene supplies such as alcohol-based hand sanitizer with at least 60% alcohol to clients experiencing homelessness or otherwise without regular access to soap and water for handwashing
Maintain harm reduction services

- Continue to provide sterile injection equipment and methods for disposal
- Continue to provide naloxone
- Consider changing policies to increase the number of syringes each client can receive per visit
- Use peer-based delivery models to ensure sterile supplies are reaching people who need them most, particularly in the event of SSP closure.
- Coordinate services with other nearby SSPs and community health programs
Continuity of care reduces the risk of infectious disease transmission

- Continue to help link clients with substance use treatment such as medication for opioid use disorder (MOUD)
  - Following SAMHSA guidance, work with programs offering MOUD and with behavioral health agencies to ensure access to 14-28 days of medication, and to initiate buprenorphine treatment using telehealth

- Consider implementing strategies such as self-testing to identify new infections

- Continue to link clients to care for HIV/AIDS, viral hepatitis, endocarditis
Technical assistance is available

NASTAD
https://www.nastad.org/domestic/hepatitis/drug-user-health
email: DrugUserHealthTA@nastad.org

Harm Reduction Coalition
THANK YOU

Questions?
Alice Asher: AAsher@cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
SSPs during COVID-19: Role, Impact, Opportunities

Daniel Raymond
@danielbraymond

Harm Reduction Coalition
www.harmreduction.org
Evolving Roles of SSPs during COVID-19

• Outreach and education: credible, trusted messengers to populations often distanced from or distrustful of officials and media

• Prevention: provision of masks, hand sanitizer, and supplies

• Testing: opportunity to provide COVID-19 testing to a medically disenfranchised population; potential role in contact tracing and future role in vaccination strategies
Initial COVID-19 Impact on SSPs

• A majority of SSPs have maintained operations, usually adapted or scaled back (Glick et al., *AIDS Behav* 2020; Bartholomew et al., *Int J Drug Policy* 2020)

• Strong signals of increased overdose fatalities reported across multiple communities; suspension of HIV & HCV testing leaves uncertainties about changes in transmission rates & potential clusters/outbreaks among people who inject drugs

• Increased regulatory flexibility in accessing MOUD (methadone, buprenorphine) may have some mitigating impact for opioid users, but overall trends in uptake and retention are uncertain
Further Opportunities for SSPs

- Remove operational barriers & burdens in current state and local policy (statutes, ordinances, regulations, funding stipulations)
- Facilitate harm reduction partnerships to address structural drivers of risk (MOUD, reentry/parole/ATI, homeless services/housing, DV/IPV, etc.)
- Protect existing funding & mobilize substantial new resources for scale-up and sustainability
Harm Reduction Coalition Resources

COVID-19 Resources for People Who Use Drugs and People Vulnerable to Structural Violence

Panelists

Braunz E. Courtney
Executive Director, HEPPAC / Casa Segura

Madison Weintraut, MPH, BSN, RN
Program Manager, Marion County Public Health Department, Syringe Access and Support (SSAS) Program

Mark Jenkins
Executive Director, Greater Hartford Harm Reduction Coalition, Inc.
HIV Education and Prevention Project of Alameda County (HEPPAC) Casa Segura

COVID-19 Adapting SSPs
Integrated Mobile Medical Model
Best Practices
ADAPTING

• Acknowledging quarantine scare and reactions (OHH $H*T)
• Board of Directors and staff buy in (Shut down, scale back, alter?)
• Review CDC, State, Local guidelines that were available DAILY!
• Brainstorming best practices, what's logical, realistic
• Impact on vulnerable populations BIPOC (ACPHD)
• Informing funders of your needs and $pending
• Becoming Zoom experts
SSP Best Practices (Taking Action)

• PPE demand, requests, stockpile for staff and participants
• Social Distancing: Staff, participants
• Shifting schedules / staggered hours
• Service Modality: Food Truck Style
• Drop In Center: Door service
• Mobile Services: Scale back at encampments
• Participants needs (Hand Washing stations) PPE
• Referrals check: Who's doing what during quarantine
Mobile Harm Reduction is still out there
Braunz E. Courtney  
Executive Director  
HEPPAC / Casa Segura  
Email: bcourtney@casasegura.org  
Website: www.casasegura.org  
Instagram: @heppac_oakland
Madison Weintraut, MPH, BSN, RN
Program Manager

Marion County Public Health Department
SAFE SYRINGE ACCESS AND SUPPORT (SSAS) PROGRAM

• Launched April 2019
• Approximately 400 clients
• Storefront and mobile locations open 5 days a week (pre-COVID)
COVID-19 Response

• Indiana shut down orders effective March 25\textsuperscript{th}
  – Storefront and mobile operations ceased March 25\textsuperscript{th} through June 5\textsuperscript{th}
  – No contact delivery model implemented

• Reported increase in EMS runs for overdose from 100 in January to 250 in April
  – No contact naloxone delivery model implemented

• Re-opened mobile outreach June 5\textsuperscript{th}
  – Exchange and naloxone provided through handicap entrance and side window
Mark Jenkins,
Executive Director
Greater Hartford Harm Reduction Coalition, Inc.
Greater Hartford Harm Reduction, Inc.
Discussion
Laura Pegram, NASTAD
druguserhealthta@nastad.org  or lpegram@nastad.org
www.nastad.org/domestic/hepatitis/drug-user-health

Daniel Raymond, Harm Reduction Coalition
@danielbraymond
www.harmreduction.org

Alice Asher, CDC
AASher@cdc.gov
www.cdc.gov/coronavirus